PVIVAX

Knowledge sharing for relapsing malaria

PVIVAX Knowledge sharing for relapsing malaria

Search

  • P. vivax malaria
    • Malaria and P. vivax malaria
    • Symptoms & severity
    • Illness and mortality
    • Populations at risk
      • Pregnant women and children
      • Migratory populations
    • Role in malaria elimination
    • Lifecycle
    • Relapses
    • Vectors
  • Diagnosis & treatment
    • Diagnostic methods
      • Microscopy
      • Rapid diagnostic tests
      • Molecular methods & serology
    • Diagnosing severe vivax malaria
    • Treatment
      • Radical cure
      • Blood stage treatment
      • Liver stage treatment
    • G6PD Deficiency
      • G6PD Global Prevalence
      • G6PD diagnostics
      • Types of G6PD clinical diagnostic tests
  • Regions & countries
    • Africa
    • Eastern Mediterranean
    • South East Asia
    • The Americas
    • Western Pacific
  • In the field
    • Projects
    • Stories and Videos
  • Tools
    • Study database
  • Resources
  • News & events
    • Past events
  • About us
Map with highlighted countries to indicate where studies are taking place

P. vivax malaria studies:  A database of studies focusing on improving access to radical cure.

View the database

Photo: istock

About the P. vivax information hub. 

Photo: istock

Featured resources

River landscape with boats

The Partnership for Vivax Elimination (PAVE)

The Partnership for Vivax Elimination (PAVE) supports countries in adopting new and existing tools and approaches to achieve universal access to the best clinical practices for P. vivax case management.
top corner of document zoomed in
05 Aug 2021

New treatment for P. vivax malaria may benefit Brazilian public health

This briefing provides an overview of the population-level transmission dynamics modelling study by Nekkab et al. on the estimated impact of tafenoquine (TQ) on control and elimination of P. vivax malaria in Brazil. The briefing is available in English, Spanish and Portuguese. 

la Alianza para la eliminación de vivax (PAVE, por sus siglas en inglés)
Fact sheet
Healthworker and patient in a consultation

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

PAVE is conducting feasibility studies and operational research to support Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals.
young man and woman sitting on a bench outside health clinic

the Tafenoquine Roll-out STudy (TRuST)

The Brazilian Ministry of Health (MoH) and MMV, are conducting a study to understand the feasibility of providing appropriate radical cure treatment (primaquine - PQ - or tafenoquine – TQ) based on the results of G6PD testing conducted in real-world settings. 
1

News

Single-dose tafenoquine 150mg tablets in palm of hand

Colombia approves single-dose medicine to prevent relapse of P. vivax malaria

03 Oct 2022
healthworkers participating in a training.

Start of ARCTIC, a feasibility study of a new Plasmodium vivax malaria treatment protocol in Thailand

22 Jul 2022
Meeting participants looking at camera

Event Highlights: The Indo-Pacific Regulatory Strengthening Program (RSP) Forum, 2022

09 May 2022
PAVE meeting participants facing the camera

Highlights from the Partnership for Vivax Elimination (PAVE) Greater Mekong Subregion (GMS) Country Coordinator Experience Exchange

30 Apr 2022
View all news
1

Events

1

Publications

18 May 2022

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA)

This is the protocol for a multicentre, health care facility-based, randomized, controlled, open-label trial ongoing in Bangladesh, Indonesia and Ethiopia. The study is evaluating the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. 

Trials
Peer-reviewed article
11 May 2022

Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria

Ley B et al.

Aim of this study was to assess the impact of acute malaria on G6PD activity. Selected patients with uncomplicated malaria were recruited in Bangladesh (n = 87), Indonesia (n = 75), and Ethiopia (n = 173); G6PD activity was measured at the initial presentation with malaria and a median of 176 days later (range 140 to 998) in the absence of malaria. Among selected participants (deficient participants preferentially enrolled in Bangladesh but not at other sites) G6PD activity fell between malaria and follow up by 79.1% (95%CI: 40.4 to 117.8) in 6 participants classified as deficient (<30% activity), 43.7% (95%CI: 34.2 to 53.1) in 39 individuals with intermediate activity (30% to <70%), and by 4.5% (95%CI: 1.4 to 7.6) in 290 G6PD normal (≥70%) participants.

PLoS Negl Trop Dis.
Peer-reviewed article
25 Apr 2022

Cost-effectiveness analysis of G6PD diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study

Aung YN et al.

This study examined the cost-effectiveness of quantitative G6PD test, with either supervised PMQ treatment or unsupervised PMQ treatment, against the usual unsupervised PMQ 8-weeks strategy. Supervised PMQ 8-weeks strategy without G6PD testing was also compared against the unsupervised PMQ 8-weeks strategy since the former had recently been adopted in malaria high burden villages that had village malaria volunteers. A budget impact analysis was conducted to understand the incremental cost and effect needed for a nationwide scale-up of the chosen strategy.

PLoS One
Peer-reviewed article
13 Apr 2022

Tafenoquine for the treatment of Plasmodium vivax malaria

Llanos-Cuentas A et al.

In this review, the authors present the recent literature regarding the pharmacology, efficacy, safety, and tolerability of TFQ and highlight regional differences in these areas. The authors also discuss the potential for TFQ, complemented with primaquine PQ and effective screening for G6PDd, to improve P. vivax clinical management and facilitate targeted mass drug administration in communities to decrease transmission.

Expert Opinion on Pharmacotherapy
Peer-reviewed article
View all publications

Get in touch

Contact us.

Submit information

Subscribe

Follow us

  • Twitter
  • LinkedIn
  • Facebook
  • Disclaimer
  • Privacy policy
A Remora website by Manta Ray Media